基于鼻咽癌逐步扩散模式的个体化原发肿瘤临床靶区勾画在调强放疗后的长期结局
本研究报告了基于逐步扩散模式的个体化原发肿瘤临床靶区勾画方案在调强放疗鼻咽癌患者中的长期疗效与毒性。回顾性分析7262例非转移性鼻咽癌患者,5年局部无复发生存率93.6%、总生存率86.0%,92.3%的局部复发为野内失败,与2018年国际指南相比该方案显著缩小了PTV70和PTV60体积。
要点
- 7262例鼻咽癌患者接受基于逐步扩散模式的个体化CTVp勾画调强放疗,5年局部无复发生存率93.6%,总生存率86.0%。
- 92.3%的局部复发和86.0%的区域复发发生在95%等剂量线内,考虑为野内失败。
- 与2018年国际指南相比,该勾画方案使早期和晚期病例的PTV70分别减少58.4%和48.3%,PTV60分别减少80.8%和62.8%。
核心结论
- 基于鼻咽癌逐步扩散模式的个体化选择性CTVp勾画方案取得了优异的长期疗效,并在等效剂量水平下较2018年国际指南缩小了照射体积。
研究设计与样本
- 回顾性评估7262例经组织学证实的非转移性鼻咽癌患者,均接受基于本机构个体化勾画方案的调强放疗。
- 采用Kaplan-Meier法估计生存率,将局部复发患者的剂量体积直方图参数与倾向性评分匹配的无局部复发患者进行比较。
- 在代表性早期和晚期鼻咽癌病例上,将本勾画方案与2018年国际指南进行剂量学比较。
主要发现
- 5年局部无复发生存率为93.6%,区域无复发生存率为94.4%,无远处转移生存率为86.8%,无进展生存率为77.8%,总生存率为86.0%。
- 92.3%的局部复发和86.0%的区域复发发生在95%等剂量线内,被认为是野内失败。
- 局部复发组与倾向性评分匹配的无复发组之间,剂量体积直方图参数无显著差异。
- 与2018年国际指南相比,本勾画方案使早期和晚期病例的PTV70分别减少58.4%和48.3%,PTV60分别减少80.8%和62.8%。
- 晚期3级毒性包括耳毒性(1.8%)、口干(0.2%)、吞咽困难(0.2%)、颞叶损伤(0.2%)和张口困难(0.1%)。
临床怎么用
- 本机构基于鼻咽癌逐步扩散模式的个体化选择性CTVp勾画方案已在本中心应用超过10年,并在此报告了长期疗效与毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our institution has developed an individualized elective primary tumor clinical target volume (CTVp) delineation protocol for nasopharyngeal carcinoma (NPC) based on stepwise tumor spread patterns in intensity modulated radiation therapy for over 10 years. Herein, we report the long-term efficacy and toxicities in patients with NPC treated under this protocol. METHODS AND MATERIALS: A total of 7262 patients with histologically proven nonmetastatic NPC treated with intensity modulated radiation therapy following this individualized delineation protocol were retrospectively evaluated. Survival rates were estimated using the Kaplan-Meier method. Dose-volume histogram parameters for patients with local relapse were compared with those of propensity score-matched without local relapse. Dosimetric comparisons of our delineation protocol with the 2018 International Guideline (2018-IG) were conducted on representative early- and advanced-stage NPC cases. RESULTS: The 5-year local relapse-free survival, regional relapse-free survival, distant metastasis-free survival, progression-free survival, and overall survival were 93.6%, 94.4%, 86.8%, 77.8%, and 86.0%, respectively. 92.3% of local relapses and 86.0% of regional relapses occurred within the 95% isodose lines and were considered in-field failures. No significant differences in dose-volume histogram parameters were observed between the local relapse group and the propensity score-matched nonrelapse group. Compared with the 2018-IG, our contouring protocol resulted in a 58.4% and 48.3% reduction in PTV70, and an 80.8% and 62.8% reduction in PTV60 for early and advanced-stage diseases, respectively. Late grade 3 toxicities included ototoxicity (1.8%), xerostomia (0.2%), dysphagia (0.2%), temporal lobe injury (0.2%), and trismus (0.1%). CONCLUSIONS: Individualized elective CTVp delineation based on the stepwise spread patterns of nasopharyngeal carcinoma achieved excellent long-term outcomes and reduced the irradiated volumes at equivalent dose levels compared with the 2018-IG.
引用
- Guo R, Zhang WW, Lv J, et al. Long-term Outcomes Following Individualized Primary Tumor Clinical Target Volume Delineation Based on Stepwise Spread Patterns of Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy. Int J Radiat Oncol Biol Phys. 2024. PMID: 39701547. doi:10.1016/j.ijrobp.2024.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。